Incyte (INCY)
(Delayed Data from NSDQ)
$51.68 USD
+0.50 (0.98%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $51.76 +0.08 (0.15%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
INCY 51.68 +0.50(0.98%)
Will INCY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for INCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INCY
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
INCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
Other News for INCY
Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)
Repare Therapeutics appoints Steven Stein to its board of directors
Incyte’s Strategic Acquisition and Promising Pipeline Secure Buy Rating
Incyte price target lowered by $10 at Argus, here's why
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)